The blood test screens individual blood donations for four common species of the parasite Babesia, which can cause anemia and other potentially fatal conditions.
The firm has launched both a public offering of common stock as well as a private placement of warrants, expecting to bring in around $20 million from the transactions.
Denisovans, an extinct group of humans, likely shared some anatomical traits with Neanderthals and humans but also had some that were specific to them.
Starting in late 2020, public health insurance is expected to pay for NIPT if a trisomy is suspected and this constitutes an "unacceptable burden" for the pregnant woman.
The industry organization issued a letter urging the agency to reconsider recent decisions to demand several laboratories stop offering pharmacogenetic testing.
BioStream will distribute the company's IsoCode and IsoLight products, which enable highly multiplexed protein measurements at the single-cell level.
The Boston-based synthetic biology firm said it will use the funds to grow its cell programing platform, which it will make available to startups.
The firm is offering approximately 13.8 million shares and the same number of warrants to purchase shares, which will be sold together.
Startup BioLizard will develop the algorithm to help Novigenix migrate its immuno-transcriptiomic assay for early colorectal cancer detection to a new NGS-based platform.
The company will collaborate the Parker Institute for Cancer Immunotherapy, Institut Gustave Roussy in France, and the University Health Network in Toronto, Canada.
The cloud-based platform is designed to process next-generation sequencing data derived from liquid biopsy and formalin-fixed paraffin embedded tissue analysis.
Under the expanded deal, PredictImmune will have first right of refusal on technologies for predicting disease outcome for systemic lupus erythematosus.
The firm said CRISPR will enable targeted sequencing of long regions of interest that were previously only accessible with long-read whole-genome sequencing.
Infants born vaginally had gut microbiomes enriched with commensal bacteria, while those born by caesarian section harbored hospital-associated bacteria.
The bill would provide additional funding to each NIH institute and center, and would follow a 5.4 percent budget increase received in fiscal 2019.
The Swiss startup plans to use the funding to support the development of genomic analysis software based on the new MPEG-G compression standard.
The German diagnostics firm recently signed an agreement to be acquired by US-based OpGen in a transaction that is slated to close in early 2020.
The credit facility, available through Sept. 17, 2024, replaces a prior credit facility dated Aug. 11, 2016 for $1 billion.
The company, founded in May 2018 and headquartered in Guangzhou in southern China, has developed a CRISPR-based rapid diagnostics platform for pathogen detection.
The partners will integrate medical information into LunaDNA pulled from electronic health records via Medfusion's application program interfaces.
The partners will use Adaptive's ClonoSeq assay to assess minimal residual disease in several of Amgen's hematology drug development programs.
The award will fund optimization of the Hemopurifier exosome isolator, with an eye towards developing applications in cancer research and clinical care.
Exome sequencing and other molecular strategies led to a heterogeneous variant in the DNMT3A gene that appears to impact host epigenetic and immune features.
The new project will be the second stage of the QSkin study, which has documented the disease in 44,000 Australians and developed a melanoma risk predictor.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.